PURPOSE: CXC chemokine receptor-4 (CXCR4) is closely involved in bone metastasis of prostate cancer, and CXCR4 levels are frequently increased in prostate cancer cells and tissues. In the present study, its biological effects on prostate cancer in vitro and in vivo and feasibility to be a therapy target were investigated using a RNA interfering retrovirus vector targeting CXCR4 gene driven by human prostate-specific antigen promoter (pPSA). METHODS: We established a pPSA-siCXCR4 retrovirus vector and transfected prostate cancer cell PC-3m, LNCaP and breast cancer cell MCF-7, respectively. The expression of CXCR4 mRNA and protein was detected by RT-PCR and western blot, and the ability of adhesion, migration, invasion of prostate cancer cells was assessed using Transwell chamber. A metastasizing model using BALB/cA mice with human bone tissue implantation was established too, and transfected prostate cancer cells were via caudal vein. Survival time of mice suffering bone metastatic tumor as well as the weight and volume of these tumors were recorded and analyzed. RESULTS: The expression of CXCR4 mRNA and protein in androgen-responsive LNCaP cells was blocked by the pPSA-siCXCR4 vector, but it could not work in non androgen-responsive PC-3m cell and breast cancer cell MCF-7. The results of experiments in vitro also showed that the adhesion, transendothelial migration and invasive ability of transfected LNCaP cells were impaired, while there was no change in PC-3m and MCF-7 cells after transfection. pPSA-siCXCR4 represented a similar inhibitory effect in fluorescent bone metastasis model of LNCaP cells compared with PC-3m cells. CONCLUSION: These results suggest that the downstream siRNA controlled by PSA promoter in retrovirus system can express selectively in androgen-responsive prostate cancer in vitro and in vivo, and CXCR4 plays an important role in prostate cancer metastasis. We believe that the pPSA-siCXCR4 retrovirus vector is a potential choice in gene therapy for androgen-responsive prostate cancer.
PURPOSE:CXC chemokine receptor-4 (CXCR4) is closely involved in bone metastasis of prostate cancer, and CXCR4 levels are frequently increased in prostate cancer cells and tissues. In the present study, its biological effects on prostate cancer in vitro and in vivo and feasibility to be a therapy target were investigated using a RNA interfering retrovirus vector targeting CXCR4 gene driven by humanprostate-specific antigen promoter (pPSA). METHODS: We established a pPSA-siCXCR4 retrovirus vector and transfected prostate cancer cell PC-3m, LNCaP and breast cancer cell MCF-7, respectively. The expression of CXCR4 mRNA and protein was detected by RT-PCR and western blot, and the ability of adhesion, migration, invasion of prostate cancer cells was assessed using Transwell chamber. A metastasizing model using BALB/cA mice with human bone tissue implantation was established too, and transfected prostate cancer cells were via caudal vein. Survival time of mice suffering bone metastatic tumor as well as the weight and volume of these tumors were recorded and analyzed. RESULTS: The expression of CXCR4 mRNA and protein in androgen-responsive LNCaP cells was blocked by the pPSA-siCXCR4 vector, but it could not work in non androgen-responsive PC-3m cell and breast cancer cell MCF-7. The results of experiments in vitro also showed that the adhesion, transendothelial migration and invasive ability of transfected LNCaP cells were impaired, while there was no change in PC-3m and MCF-7 cells after transfection. pPSA-siCXCR4 represented a similar inhibitory effect in fluorescent bone metastasis model of LNCaP cells compared with PC-3m cells. CONCLUSION: These results suggest that the downstream siRNA controlled by PSA promoter in retrovirus system can express selectively in androgen-responsive prostate cancer in vitro and in vivo, and CXCR4 plays an important role in prostate cancer metastasis. We believe that the pPSA-siCXCR4 retrovirus vector is a potential choice in gene therapy for androgen-responsive prostate cancer.
Authors: T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531
Authors: Ombretta Salvucci; Amélie Bouchard; Andrea Baccarelli; Jean Deschênes; Guido Sauter; Ronald Simon; Rosella Bianchi; Mark Basik Journal: Breast Cancer Res Treat Date: 2005-12-13 Impact factor: 4.872
Authors: Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205
Authors: A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot Journal: Science Date: 1999-02-05 Impact factor: 47.728
Authors: Alessandro Ottaiano; Antonella di Palma; Maria Napolitano; Carmen Pisano; Sandro Pignata; Fabiana Tatangelo; Gerardo Botti; Angela Maria Acquaviva; Giuseppe Castello; Paolo Antonio Ascierto; Rosario Vincenzo Iaffaioli; Stefania Scala Journal: Cancer Immunol Immunother Date: 2004-12-11 Impact factor: 6.968
Authors: Maggie C Louie; Hong Qiong Yang; Ai-Hong Ma; Wei Xu; June X Zou; Hsing-Jien Kung; Hong-Wu Chen Journal: Proc Natl Acad Sci U S A Date: 2003-02-14 Impact factor: 11.205
Authors: M Yang; P Jiang; F X Sun; S Hasegawa; E Baranov; T Chishima; H Shimada; A R Moossa; R M Hoffman Journal: Cancer Res Date: 1999-02-15 Impact factor: 12.701
Authors: Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow Journal: Mol Cancer Date: 2010-11-18 Impact factor: 27.401
Authors: Daniel E Frigo; Andrea B Sherk; Bryan M Wittmann; John D Norris; Qianben Wang; James D Joseph; Aidan P Toner; Myles Brown; Donald P McDonnell Journal: Mol Endocrinol Date: 2009-05-21